Insulet Corp
NASDAQ:PODD
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
152.88
239.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Insulet Corp
Intrinsic Value
The intrinsic value of one
PODD
stock under the Base Case scenario is
93.59
USD.
Compared to the current market price of 237.44 USD,
Insulet Corp
is
Overvalued by 61%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Insulet Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PODD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Insulet Corporation is a pioneering medical device company, primarily recognized for its innovative Omnipod Insulin Management System, which revolutionizes diabetes care. Founded in 2000, Insulet has focused on developing patch pump technology that offers a seamless, tubeless insulin delivery solution for individuals with insulin-dependent diabetes. This cutting-edge product allows users to manage their insulin delivery discreetly and conveniently, enhancing their quality of life and simplifying the complex regimen of diabetes management. As the prevalence of diabetes continues to rise globally, Insulet stands at the forefront of meeting a substantial medical need, capturing a significant ma...
Insulet Corporation is a pioneering medical device company, primarily recognized for its innovative Omnipod Insulin Management System, which revolutionizes diabetes care. Founded in 2000, Insulet has focused on developing patch pump technology that offers a seamless, tubeless insulin delivery solution for individuals with insulin-dependent diabetes. This cutting-edge product allows users to manage their insulin delivery discreetly and conveniently, enhancing their quality of life and simplifying the complex regimen of diabetes management. As the prevalence of diabetes continues to rise globally, Insulet stands at the forefront of meeting a substantial medical need, capturing a significant market share with its user-friendly technology.
As an investor, understanding Insulet’s growth trajectory and market potential is essential. The company has witnessed consistent revenue growth, driven by increased adoption of its Omnipod systems, and has expanded its product portfolio to include a new generation of devices that offer even greater functionality. Insulet is also heavily investing in research and development to further innovate its offerings, positioning itself competitively in the fast-evolving diabetes care market. With strong industry partnerships and a commitment to enhancing user experience, Insulet represents not just a promising investment in healthcare technology but also a company that is fundamentally improving the lives of millions.
Insulet Corporation is primarily known for its innovative medical devices, particularly in the diabetes management space. Its core business segments can be summarized as follows:
-
Omnipod Insulin Management System: This is Insulet's flagship product, which consists of an insulin delivery system used by patients with diabetes. The Omnipod system includes a wearable insulin pod that is free of tubing, allowing for greater freedom and flexibility compared to traditional insulin pumps. This segment is central to Insulet’s business model and involves ongoing development and improvement of the product.
-
Omnipod Horizon System: This is an advanced version of the Omnipod system that integrates continuous glucose monitoring (CGM) technology with the insulin delivery system. It aims to automate insulin delivery based on real-time glucose levels, thereby improving patient outcomes through better glucose control.
-
International Markets: Insulet is expanding its reach beyond the United States by selling its products in international markets. The company has been focusing on increasing its presence in Europe, Canada, and other regions, adapting its marketing and distribution strategies to cater to varying healthcare systems and regulations.
-
Partnerships and Collaborations: Insulet often engages in collaborations with other companies, including technology and pharmaceutical firms, to enhance its product offerings. These partnerships can involve integrating additional technologies, like advanced software solutions for diabetes management.
-
Research and Development (R&D): A pivotal aspect of Insulet’s strategy is its investment in R&D to innovate and improve its existing products and develop new technologies. This continuous improvement helps maintain their competitive edge in the diabetes care market.
Overall, Insulet’s core business segments revolve around providing innovative solutions for diabetes management, focusing on convenience, efficiency, and improved patient outcomes. The company’s strategy is centered on leveraging technology to enhance the quality of care for individuals with diabetes, which is expected to drive growth in the future.
Insulet Corporation, known for its Omnipod insulin management system, has several unique competitive advantages that distinguish it from its rivals in the diabetes management market:
-
Innovative Technology: Insulet’s Omnipod system is wireless and tubeless, offering a level of convenience and discretion that appeals to many users. The integration of continuous glucose monitoring (CGM) with their automated insulin delivery makes their system user-friendly and reduces the burden of managing diabetes.
-
User-Centric Design: The design of the Omnipod system emphasizes ease of use and comfort. Users do not have to deal with tubing, which makes it more appealing for active individuals and those seeking a less intrusive method of insulin delivery.
-
Strong Brand Loyalty: The company has built a loyal customer base due to the effectiveness of its products and excellent customer service. This loyalty can translate into repeat business and positive word-of-mouth recommendations.
-
Regulatory Approvals and Recognitions: Insulet has received several regulatory approvals, including from the FDA, which adds to the credibility and trust of their product. These approvals are critical in the medical device industry and can create a barrier to entry for competitors.
-
Partnerships and Collaborations: Insulet has established strategic partnerships with other companies in the healthcare space, such as with diabetes management technology platforms. These collaborations enhance its product offerings and accessibility.
-
Focus on Continuous Innovation: Insulet is committed to research and development, continually improving its existing products and developing new solutions. This dedication to innovation allows it to stay ahead of competitors and meet evolving patient needs.
-
Market Focus: Insulet focuses specifically on insulin delivery and diabetes management, which allows it to tailor its resources and research to meet the needs of this specific market. This specialization can lead to deeper market insights and more effective product development.
-
Adaptability to Changing Market Needs: The company has shown agility in adapting to new trends in diabetes care, such as enhancing connectivity with smart devices and incorporating data analytics to improve user experience and health outcomes.
By leveraging these competitive advantages, Insulet Corp positions itself as a leader in the diabetes management market, striving to improve the lives of individuals with diabetes while maintaining a robust growth trajectory.
Insulet Corp, known for its Omnipod insulin delivery systems, faces several risks and challenges that could impact its business in the near future:
-
Regulatory Risks: The medical device industry is highly regulated. Compliance with FDA guidelines and obtaining necessary approvals for new products or modifications can be a lengthy and costly process. Any delays or complications can impact market entry and revenue.
-
Market Competition: Insulet operates in a competitive landscape with other companies offering insulin delivery systems, continuous glucose monitors, and other diabetes management solutions. New entrants or innovations from competitors can threaten Insulet's market share.
-
Technological Advancements: Rapid technological change in diabetes management devices requires continuous investment in research and development. Insulet must innovate to meet consumer needs and keep pace with advancements such as automated insulin delivery systems and integration with health apps.
-
Supply Chain Disruptions: Global supply chain issues, exacerbated by events like the COVID-19 pandemic, can lead to shortages of raw materials or delays in production. This can impact product availability, sales, and ultimately customer satisfaction.
-
Reimbursement Challenges: The healthcare reimbursement landscape can be complex and varies by region. Changes in reimbursement policies or delays in securing coverage for new products could hinder sales growth.
-
Market Acceptance: The success of new products, like next-generation insulin delivery systems, relies on market acceptance. If healthcare providers and patients are slow to adopt new technologies, this could impact sales.
-
Cybersecurity Threats: As medical devices become more connected, the potential for cybersecurity breaches increases. Protecting patient data and securing devices against cyber threats is crucial for maintaining trust and compliance.
-
Litigation Risks: Like many medical device companies, Insulet could be subject to lawsuits related to product liability or patent infringement, which can be costly and damage reputation.
-
Economic Factors: Economic downturns can impact patient spending and healthcare expenditures. Insurance coverage changes and economic pressures could lead to reduced sales.
-
Global Market Dynamics: Insulet's operations involve international markets, which may expose it to currency fluctuations, geopolitical risks, and variations in healthcare regulations across different countries.
Addressing these risks involves strategic planning, continual market research, and a robust approach to product development and customer engagement.
Revenue & Expenses Breakdown
Insulet Corp
Balance Sheet Decomposition
Insulet Corp
| Current Assets | 1.7B |
| Cash & Short-Term Investments | 715.5m |
| Receivables | 348.6m |
| Other Current Assets | 684.7m |
| Non-Current Assets | 1.1B |
| PP&E | 677.9m |
| Intangibles | 150.2m |
| Other Non-Current Assets | 304.7m |
| Current Liabilities | 486m |
| Accounts Payable | 76.8m |
| Accrued Liabilities | 371.3m |
| Other Current Liabilities | 37.9m |
| Non-Current Liabilities | 1.4B |
| Long-Term Debt | 1.4B |
| Other Non-Current Liabilities | 37.3m |
Earnings Waterfall
Insulet Corp
|
Revenue
|
1.9B
USD
|
|
Cost of Revenue
|
-580.5m
USD
|
|
Gross Profit
|
1.3B
USD
|
|
Operating Expenses
|
-1B
USD
|
|
Operating Income
|
272.7m
USD
|
|
Other Expenses
|
122.6m
USD
|
|
Net Income
|
395.3m
USD
|
Free Cash Flow Analysis
Insulet Corp
| USD | |
| Free Cash Flow | USD |
Insulet Corporation reported a robust second quarter in 2024, driven by a 26% growth in Omnipod revenue. The company’s U.S. revenue rose by 27%, while international sales increased by 24%. This success is largely attributed to the growing demand for Omnipod 5 and strategic market expansion. As a result, Insulet raised its full-year revenue growth guidance to 18-21%. The firm also highlighted its ongoing innovations and market leadership in automated insulin delivery. With the planned global expansion of Omnipod 5 and a new manufacturing facility in Malaysia, Insulet remains optimistic about further revenue and margin improvements in the future.
What is Earnings Call?
PODD Profitability Score
Profitability Due Diligence
Insulet Corp's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Insulet Corp's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
PODD Solvency Score
Solvency Due Diligence
Insulet Corp's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Insulet Corp's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PODD Price Targets Summary
Insulet Corp
According to Wall Street analysts, the average 1-year price target for
PODD
is 252.59 USD
with a low forecast of 186.85 USD and a high forecast of 299.25 USD.
Click here to dive deeper.
Dividends
Current shareholder yield for PODD is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PODD Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Profile
Insulet Corp
Country
Industry
Market Cap
Dividend Yield
Description
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 2,300 full-time employees. The company went IPO on 2007-05-15. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. The company can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.
Contact
IPO
Employees
Officers
The intrinsic value of one
PODD
stock under the Base Case scenario is
93.59
USD.
Compared to the current market price of 237.44 USD,
Insulet Corp
is
Overvalued by 61%.
You don't have any saved screeners yet
